ATE345353T1 - Langwirkende fusionspeptidinhibitoren gegen hiv- infektion - Google Patents

Langwirkende fusionspeptidinhibitoren gegen hiv- infektion

Info

Publication number
ATE345353T1
ATE345353T1 AT04015696T AT04015696T ATE345353T1 AT E345353 T1 ATE345353 T1 AT E345353T1 AT 04015696 T AT04015696 T AT 04015696T AT 04015696 T AT04015696 T AT 04015696T AT E345353 T1 ATE345353 T1 AT E345353T1
Authority
AT
Austria
Prior art keywords
long
virus
hiv infection
fusion peptide
against hiv
Prior art date
Application number
AT04015696T
Other languages
English (en)
Inventor
John Erickson
Dominique P Bridon
Martin Robitaille
Grant A Krafft
Dong Xie
Elena Afonina
Jun Liang
Meyer Sandra De
Original Assignee
Conjuchem Biotechnologies Inc
John Erickson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Biotechnologies Inc, John Erickson filed Critical Conjuchem Biotechnologies Inc
Application granted granted Critical
Publication of ATE345353T1 publication Critical patent/ATE345353T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04015696T 2001-05-31 2002-05-31 Langwirkende fusionspeptidinhibitoren gegen hiv- infektion ATE345353T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29424101P 2001-05-31 2001-05-31

Publications (1)

Publication Number Publication Date
ATE345353T1 true ATE345353T1 (de) 2006-12-15

Family

ID=23132509

Family Applications (3)

Application Number Title Priority Date Filing Date
AT04015696T ATE345353T1 (de) 2001-05-31 2002-05-31 Langwirkende fusionspeptidinhibitoren gegen hiv- infektion
AT02729737T ATE295370T1 (de) 2001-05-31 2002-05-31 Langwirkende fusionspeptid-inhibitoren für hiv- infektion
AT06023309T ATE412667T1 (de) 2001-05-31 2002-05-31 Langwirkende fusionspeptidinhibitoren gegen hiv- infektion

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT02729737T ATE295370T1 (de) 2001-05-31 2002-05-31 Langwirkende fusionspeptid-inhibitoren für hiv- infektion
AT06023309T ATE412667T1 (de) 2001-05-31 2002-05-31 Langwirkende fusionspeptidinhibitoren gegen hiv- infektion

Country Status (12)

Country Link
US (2) US7741453B2 (de)
EP (1) EP1390399B1 (de)
JP (2) JP4463545B2 (de)
AT (3) ATE345353T1 (de)
AU (1) AU2002302277A1 (de)
CA (1) CA2448891A1 (de)
DE (3) DE60229677D1 (de)
DK (1) DK1479691T3 (de)
ES (2) ES2242860T3 (de)
HK (1) HK1071379A1 (de)
PT (1) PT1479691E (de)
WO (1) WO2002096935A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
ES2209885T3 (es) * 1999-05-17 2004-07-01 Conjuchem, Inc. Peptidos insulinotropicos de larga duracion.
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
JP4216480B2 (ja) * 1999-05-17 2009-01-28 コンジュケム バイオテクノロジーズ インコーポレイテッド ウイルス感染の長期持続性融合ペプチドインヒビター
JP4280070B2 (ja) 2001-02-16 2009-06-17 コンジュケム バイオテクノロジーズ インコーポレイテッド 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２）
ES2242860T3 (es) 2001-05-31 2005-11-16 Conjuchem, Inc. Inhibidores peptidicos de fusion de larga vida contra infecciones por vih.
NZ567952A (en) * 2003-03-24 2009-12-24 Sequoia Pharmaceuticals Inc Long acting biologically active conjugates
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
WO2005056752A2 (en) 2003-10-24 2005-06-23 Gencia Corporation Methods and compositions for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
BRPI0510117A (pt) * 2004-04-23 2007-09-25 Conjuchem Biotechnologies Inc método para purificação de conjugados de albumina
JP2008505059A (ja) * 2004-05-06 2008-02-21 コンジュシェム バイオテクノロジーズ インコーポレイティド 特異的ウイルス標的用化合物
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
US20070269863A1 (en) * 2005-12-22 2007-11-22 Bridon Dominique P Process for the production of preformed conjugates of albumin and a therapeutic agent
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
CA2687700A1 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Cysteic acid derivatives of anti-viral peptides
WO2008144590A2 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Long lasting modified antifusogenic peptide for preventing hiv infection
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
CN102026666B (zh) * 2007-12-11 2013-10-16 常山凯捷健生物药物研发（河北）有限公司 促胰岛素肽缀合物制剂
US8815295B1 (en) 2011-12-22 2014-08-26 Alabama State University Anti respiratory syncytial virus peptide functionalized gold nanoparticles
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652629A (en) 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO1994002505A1 (en) 1992-07-20 1994-02-03 Duke University Compounds which inhibit hiv replication
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP0602290B1 (de) 1992-12-04 1999-08-25 ConjuChem, Inc. Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US6017536A (en) 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
WO1996005389A1 (en) 1994-08-15 1996-02-22 B-Level Corp. Auxiliary surface-forming member for construction elements
US6103236A (en) 1995-05-10 2000-08-15 Kyowa Hakko Kogyo Co., Ltd. Toxin conjugates
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US6150088A (en) 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
WO1999024076A2 (en) 1997-11-07 1999-05-20 Conjuchem, Inc. Salicylate derivatized therapeutic and diagnostic agents
ES2178854T3 (es) 1997-11-07 2003-01-01 Conjuchem Inc Bibliotecas de marcadores de afinidad para albumina de suero humano.
US6107489A (en) 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
IL133053A0 (en) 1998-03-23 2001-03-19 Conjuchem Inc Local delivery of long lasting therapeutic agents
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
BR9914519A (pt) 1998-10-13 2001-07-03 Univ Georgia Res Found Peptìdios bioativos estabilizados e métodos de identificação, sìntese e uso
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
EP1149115A4 (de) 1999-01-08 2005-11-02 Panacos Pharmaceuticals Inc Verfahren zum hervorrufen von breit wirksamen, neutralisierenden antikörpern, die gegen gp41 von hiv-1 gerichtet sind.
CN1698881A (zh) 1999-05-17 2005-11-23 康久化学公司 病毒感染的长效融合肽抑制剂
ES2209885T3 (es) 1999-05-17 2004-07-01 Conjuchem, Inc. Peptidos insulinotropicos de larga duracion.
JP4216480B2 (ja) 1999-05-17 2009-01-28 コンジュケム バイオテクノロジーズ インコーポレイテッド ウイルス感染の長期持続性融合ペプチドインヒビター
EP1591453A1 (de) 1999-05-17 2005-11-02 ConjuChem Inc. Modifizierte YY-Peptide und ihre Konjugate
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
WO2001017568A2 (en) 1999-09-07 2001-03-15 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
US7053179B2 (en) 1999-12-16 2006-05-30 Whitehead Institute For Biomedical Research Five-Helix protein
ES2242860T3 (es) 2001-05-31 2005-11-16 Conjuchem, Inc. Inhibidores peptidicos de fusion de larga vida contra infecciones por vih.
WO2004029201A2 (en) 2002-09-24 2004-04-08 Frontier Biotechnologies Co., Ltd Peptide derivative fusion inhibitors of hiv infection
US7556813B2 (en) 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
EP1543166A4 (de) 2002-09-27 2009-10-28 Genentech Inc Synergetische zusammensetzungen zur vorbeugung und behandlung des erworbenen immunschwäche-syndroms
WO2005007831A2 (en) 2003-07-18 2005-01-27 Vanderbilt University Compositions of protein mimetics and methods of using same against hiv-1, sars-cov and the like
BRPI0510117A (pt) 2004-04-23 2007-09-25 Conjuchem Biotechnologies Inc método para purificação de conjugados de albumina
JP2008505059A (ja) 2004-05-06 2008-02-21 コンジュシェム バイオテクノロジーズ インコーポレイティド 特異的ウイルス標的用化合物
US20070269863A1 (en) 2005-12-22 2007-11-22 Bridon Dominique P Process for the production of preformed conjugates of albumin and a therapeutic agent

Also Published As

Publication number Publication date
CA2448891A1 (en) 2002-12-05
EP1390399A2 (de) 2004-02-25
US20050065075A1 (en) 2005-03-24
DE60204137D1 (de) 2005-06-16
ATE295370T1 (de) 2005-05-15
JP2008308506A (ja) 2008-12-25
ES2277173T3 (es) 2007-07-01
AU2002302277A1 (en) 2002-12-09
JP4463545B2 (ja) 2010-05-19
JP2005500274A (ja) 2005-01-06
ES2242860T3 (es) 2005-11-16
DE60229677D1 (de) 2008-12-11
DK1479691T3 (da) 2007-03-12
DE60216151D1 (de) 2006-12-28
US20110166061A1 (en) 2011-07-07
DE60216151T2 (de) 2007-09-27
WO2002096935A2 (en) 2002-12-05
US7741453B2 (en) 2010-06-22
DE60204137T2 (de) 2006-01-26
EP1390399B1 (de) 2005-05-11
WO2002096935A3 (en) 2003-10-02
HK1071379A1 (en) 2005-07-15
PT1479691E (pt) 2007-02-28
ATE412667T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
ATE345353T1 (de) Langwirkende fusionspeptidinhibitoren gegen hiv- infektion
NO20051969L (no) Nukleosidderivater for behandling av hepatitt C virusinfeksjon.
ATE387208T1 (de) Antivirale mittel aus pflanzenextrakten und deren verwendung zur behandlung viraler infektionen
WO2008144584A3 (en) Cysteic acid derivatives of anti-viral peptides
DE602006015861D1 (de) Antivirale verbindungen
ATE264914T1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
ATE541844T1 (de) Antivirale verbindungen
WO2003051306A3 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
NO20070194L (no) Fremgangsmater for behandling av hepatitt C
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
BRPI0507675A (pt) derivados de 2'-c-metil nucleosìdeo
WO2007033444A3 (en) Antiviral therapy with carbohydrate binding agents
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
WO2008118849A3 (en) Hiv-1 protease inhibitors
CR7806A (es) Inhibidores de la fusion de derivados peptidos de la infeccion vih
DK1334119T3 (da) Sammensætninger og fremgangsmåder til modulering af RSV-infektion og -immunitet
BR0210158A (pt) Derivados de pirazol como inibidores da transcriptase reversa do hiv
DK1765370T3 (da) Parapox-vira i kombination med andre antivirale midler til behandling af HIV/AIDS
WO2004052905A3 (en) Antiviral nucleoside derivatives
ATE478679T1 (de) Verfahren zur anwendung von ionisierungsstrahlung bei einer hiv-infektionstherapie
EP1752469A3 (de) Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
WO2008144590A3 (en) Long lasting modified antifusogenic peptide for preventing hiv infection
CY1105997T1 (el) Mακρας διαρκειας αναστολεις πεπτιδιου συντηξης για μολυνση hiv
ATE481413T1 (de) Glutathionderivate und deren verwendung zur behandlung von viralen erkrankungen
EP1546415A4 (de) Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1479691

Country of ref document: EP